2024 - AI-based Antibody Therapeutics Developability Assessment and Its Engineering

Learn from an informative webinar about how AI-based platforms can facilitate the development process for antibody therapeutics and ensure candidates are not only therapeutically effective but also viable for large-scale production and clinical use.
Monoclonal antibodies (mAbs) have become essential in treating a wide spectrum of diseases, with over 100 therapeutic antibody products now approved and commercially available. Although mAbs represent the fastest-growing sector in therapeutics, their development is complex, with developability being a crucial consideration. Developability evaluates the potential of an antibody candidate to be produced as a safe and effective drug.
In the context of Contract Research and Manufacturing Organizations (CRMOs), the developability assessment focuses on ensuring that an antibody candidate can progress through the chemistry, manufacturing and control (CMC) processes efficiently, affordably and within an acceptable timeframe.
Read more...
Register for this webinar today to learn how AI can be used to improve developability screening of antibody therapeutics and optimization of antibody candidates.
Keywords: Antibodies, Drug Development, Antibody, Drug Discovery, CRO, Monoclonal Antibodies, AI, Antibody-Drug Conjugate, Monoclonal Antibody, Monoclonal Antibody Development, CDMO/CMO